Katharine Dunlop

B. W. Dunlop (full given name not provided) is a clinician–researcher active in contemporary psychedelic clinical research with a focus on affective and anxiety‑related disorders. Drawing on a programme of randomised, placebo‑controlled trials and longitudinal observational studies, Dunlop has contributed to investigations of MDMA’s acute and subacute effects on personality, affective state, and fear extinction retention in healthy volunteers, and to clinical studies of single‑dose psilocybin for treatment‑resistant major depressive episodes and long‑term follow‑up of those outcomes.

Dunlop’s work also spans methodological innovation in outcome prediction, including the application of natural language processing to predict clinical response to psilocybin therapy. Across these studies, the emphasis is on translational clinical endpoints — symptom change in depressive and anxiety disorders, mechanisms related to fear extinction and affect regulation, and predictors of durable therapeutic response — positioning Dunlop as a contributor to both therapeutic development and mechanistic understanding within psychedelic psychiatry. Please supply the researcher’s full first name or additional identifiers to enable a more complete bibliographic and institutional profile.